High-Dose Treatment With Telmisartan Induces Monocytic Peroxisome Proliferator-Activated Receptor-γ Target Genes in Patients With the Metabolic Syndrome-Reference-Cited by-同舟云学术

High-Dose Treatment With Telmisartan Induces Monocytic Peroxisome Proliferator-Activated Receptor-γ Target Genes in Patients With the Metabolic Syndrome

Published:2011-10 Issue:4 Volume:58 Page:725-732
ISSN:0194-911X
Container-title:Hypertension
language:en
Short-container-title:Hypertension

Author:

Bähr Ilse-Nirmala¹,Tretter Patrizia¹,Krüger Janine¹,Stark Renee G.¹,Schimkus Julia¹,Unger Thomas¹,Kappert Kai¹,Scholze Jürgen¹,Parhofer Klaus G.¹,Kintscher Ulrich¹

Affiliation:

1. From the Center for Cardiovascular Research, Institute of Pharmacology (I.-N.B., T.U., U.K.), and Center for Cardiovascular Research, Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry (J.K., K.K.), and Department of Medicine (J. Schi., J. Scho.), Outpatient Clinic, Charité Campus Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany; Department of Internal Medicine II (P.T., K.G.P.), University Hospital Großhadern, Ludwig-Maximillians-University, Munich, Germany;...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

Reference38 articles.

1. Effective treatment of hypertension by AT1receptor antagonism: the past and future of telmisartan

2. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

3. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

4. Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating Activity

5. Molecular Characterization of New Selective Peroxisome Proliferator–Activated Receptor γ Modulators With Angiotensin Receptor Blocking Activity

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID‐19;Pharmacology Research & Perspectives;2023-04

2. Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Mayo Clinic Proceedings;2022-10

3. Renin-angiotensin system inhibitors combined with cisplatin exacerbate cisplatin-induced nephrotoxicity in mice;Translational Oncology;2022-04

4. Modulation of insulin resistance by renin angiotensin system inhibitors: implications for cardiovascular prevention;Monaldi Archives for Chest Disease;2021-03-11

5. Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis;Ageing Research Reviews;2018-09